medRxiv preprint doi: https://doi.org/10.1101/2021.08.13.21262006; this version posted August 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Perpetuity. All rights reserved. No reuse allowed without permission.

1

2 Altered increase in STAT1 expression and phosphorylation in severe COVID-19

Hector Rincon-Arevalo^{1,2,3,4+}, Arman Aue^{1,2,3+}, Jacob Ritter^{2,6}, Franziska Szelinski^{2,3}, Dmytro 3 Khadzhynov¹, Daniel Zickler¹, Luisa Stefanski², Andreia C. Lino³, Sixten Körper⁵, Kai-Uwe 4 Eckardt¹, Hubert Schrezenmeier⁵, Thomas Dörner^{2,3+} and Eva V. Schrezenmeier^{1,2,6+} 5

- 6 ¹Department of Nephrology and Medical Intensive Care, Charité- Universitätsmedizin Berlin, 7 Berlin, Germany.
- ²Department of Rheumatology and Clinical Immunology, Charité- Universitätsmedizin Berlin, 8 Berlin, Germany, 9
- ³Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany. 10

⁴Grupo de Inmunología Celular e Inmunogenética, Facultad de Medicina, Instituto de 11 Investigaciones Médicas, Universidad de Antioquia UdeA, Medellín, Colombia. 12

⁵Institute for Clinical Transfusion Medicine and Immunogenetics Ulm. German Red Cross 13 14 Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm; and Institute of Transfusion Medicine, University of Ulm 15

- 16 ⁶Berlin Institute of Health (BIH)
- 17 *these authors contributed equally.

Corresponding Author: 18

- Eva V. Schrezenmeier, MD 19
- Department of Nephrology and Medical Intensive Care, Charité- Universitätsmedizin Berlin, 20 Berlin, Germany. 21
- Chariteplatz 1, 10117 Berlin, Germany 22
- 23 Email: eva-vanessa.schrezenmeier@charite.de

24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
37	

perpetuity. All rights reserved. No reuse allowed without permission.

38 Abstract

39 The interferon pathway represents a key antiviral defense mechanism and is being considered as a therapeutic target in COVID-19. Both, substitution of interferon and blocking interferon 40 41 signaling through JAK STAT inhibition to limit cytokine storms have been proposed. However, little is known so far about possible abnormalities in STAT signaling in immune cells during 42 43 SARS-CoV-2 infection. In the current study, we investigated downstream targets of interferon signaling, including STAT1, pSTAT1 and 2 and IRF1, 7 and 9 by flow cytometry in 30 patients 44 45 with COVID-19, 17 with mild and 13 with severe infection. We report an upregulation of STAT1 and IRF9 in mild and severe COVID-19 cases, which correlated with the IFN-signature 46 47 assessed by Siglec-1 (CD169) expression on peripheral monocytes. Most interestingly, Siglec-1 and STAT1 in CD14+ monocytes and plasmablasts showed lower expression among severe 48 49 COVID-19 cases compared to mild cases. Contrary to the baseline whole protein STAT1 expression, the phosphorylation of STAT1 was enhanced in severe COVID-19 cases, 50 indicating a dysbalanced JAK STAT signaling that fails to induce transcription of interferon 51 stimulated response elements (ISRE). This abnormality persisted after IFN- α and IFN- γ 52 stimulation of PBMCs from patients with severe COVID-19. The data suggest impaired STAT1 53 transcriptional upregulation among severely infected patients which may represent a potential 54 predictive biomarker and may allow stratification of patients for certain interferon-pathway 55 56 targeted treatments.

57

59

1. Introduction 58

Following viral infection, a complex regulatory system of innate and adaptive immune 60 61 mechanisms is initiated to defend against viral invasion. One of many responses to viral infection is the induction of the pleiotropic cytokine interferon (IFN) [1]. It acts as a key link 62 between the innate and adaptive immune system. IFN- α (type I IFN) is mainly secreted by 63 64 plasmacytoid dendritic cells (pDCs), while IFN-y (type II IFN) is predominantly produced by 65 natural killer cells and by certain T cells and macrophages. Both, type I and type II IFN, have diverse but complementary antiviral effects such as induction of apoptosis and activation of 66 macrophages, natural killer (NK) cells as well as B and T lymphocytes [2, 3]. 67

Regarding severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection, IFN 68 69 related antiviral response attracted attention since inborn errors of type I IFN and the presence 70 of autoantibodies against type I IFN were found to be associated with a severe course of the disease [4, 5]. Roughly 10% of coronavirus disease 2019 (COVID-19) patients with severe 71 pneumonia produce neutralizing autoantibodies against IFNa, IFNa, or both, while patients 72 with no or mild disease have no detectable autoantibodies [4]. Further, it has been shown that 73 74 patients with severe COVID-19 have a highly impaired IFN type I signature, with reduced IFN-75 α production and activity [6].

76 Type I IFNs signal through Janus kinase (JAK) and signal transducer and activator of 77 transcription (STAT) pathway and thereby stimulate gene expression. After specific binding to the IFN-q receptor (IFNAR), consisting of two chains (IFNAR1 and IFNAR2). 78 autophosphorylation of the newly formed complex leads to phosphorylation of the receptor-79 associated JAK1 and TYK2 [7, 8]. Subsequently, further phosphorylation of cytoplasmatic 80 STAT1 and STAT2 induces its dimerization and interaction with IFN regulatory factor 9 (IRF9), 81 82 a strong enhancer of translocation to the nucleus [9-11]. The activation of STAT1 is achieved by tyrosine phosphorylation on Y701 that is followed by nuclear accumulation [12]. 83

Formation of a complex called interferon-stimulated gene factor 3 (ISGFR3) binding to IFN-84 stimulated response elements (ISRE) finally results in stimulation of gene expression [12]. 85 Likewise the same sequence of biochemical processes leads to the transcriptional influence 86 of IFN-y (type II IFN), involving the IFN-y receptor (IFNGR), JAK1 and JAK2, and dimerization 87 88 of the homodimer STAT1 binding to IFN-y-activated site (GAS) [1]. Figure 1A schematically

All rights reserved. No reuse allowed without permission.

depicts JAK/STAT signaling. Although it has been shown that the virus proteins NSP5, ORF7a, N and ORF6 are able to directly interfere with JAK STAT signaling by inhibiting translocation of STATs or inhibiting their phosphorylation in SARS-CoV-2 infected cultured cells [13, 14], it is not fully understood how JAK STAT signaling is altered in immune cells and if a dysbalance in JAK STAT signaling may contribute to disease severity.

Here we report an increased STAT1 expression in mild and severe COVID-19 patients compared to controls. Severe COVID cases showed lower STAT1 expression than mild patients, accompanied by elevated phosphorylation of STAT1 at the pY701 phosphosite suggesting a disturbance of signal transduction related to impaired STAT1 transcription, which is not surmountable by additional IFN stimulation.

100 **2.** Methods

101102 2.1. Study participants

103 104 Peripheral blood samples (EDTA anti-coagulated, BD vaccutainer system, BD Diagnostics, Franklin Lakes, NJ, USA) from 20 healthy controls and 30 COVID patients were analyzed, 17 105 106 with mild (WHO 8-point ordinal scale 1 and 2) and 13 with a severe course of the disease 107 (WHO 8-point ordinal scale \geq 4) [15]. Donor information is summarized in Table 1. Severe cases were participants in the CAPSID trial that investigated convalescent plasma therapy 108 (EudraCT2020-001210-38; NCT04433910I). Samples for this study were collected at baseline 109 prior to administration of the investigation drug. All participants or their legal representatives 110 111 gave written informed consent according to the approval of the ethics committee at the Charité University Hospital, Berlin (EA2/066/20 Pa-Covid-19 and University of Ulm (CAPSID trial 112 113 (115/20 and 488/20) [16, 17].

114

115 **2.2.** Analytical methods and flow cytometry

116

117 Intracellular phenotyping of STAT1, pSTAT1, pSTAT2, IRF1 and IRF7 levels in B and T cells was conducted as previously published [18]. Briefly, peripheral whole blood (500 µl) was lysed 118 119 and fixed the same day of acquisition using 5 ml BD Phosflow Lyse/Fix Buffer (BD Biosciences, San Jose, CA, USA, 10 min, 37°C) considering the manufacturer's protocol (mix of 1:5 in aqua 120 121 dest). After two washing steps using ice-cold PBS Dulbecco (Biochrom GMBH, Berlin, 122 Germany) (530 g, 8 min, 4°C), permeabilization was performed using 200 µl BD Perm Buffer II (BD Biosciences, San Jose, CA, USA; 12h, -20°C), followed by overnight storage at -20°C. 123 Next, cells were washed twice with PBS Dulbecco containing 0.5% BSA/EDTA (530 xg, 8 min, 124 4°C) and resuspended in 50 µl of PBS with 20% Brilliant Buffer (BD Horizon, San Jose, CA, 125 USA). After incubation with 2.5 µl of FcR blocking reagent (Miltenyi Biotec Bergisch Gladbach, 126 127 NRW, Germany) for 5 min, staining for 1 h and subsequent flow cytometry analysis were 128 carried out at the same day.

All flow cytometry analyses were performed using a BD FACS Fortessa (BD Biosciences, 129 Franklin Lakes, NJ, USA). To ensure comparable mean fluorescence intensities (MFIs) over 130 time of the analyses, Cytometer Setup and Tracking beads (CST beads, BD Biosciences, 131 132 Franklin Lakes, NJ, USA) and Rainbow Calibration Particles (BD Biosciences, Franklin Lakes, NJ, USA) were used. For flow cytometric analysis, the following fluorochrome-labeled 133 antibodies were used: BUV395 anti-CD14 (BD, clone M5E2, 1:50), PE-Cy7 anti-CD3 (BD, 134 135 clone UCHT1, 1:100), BV510 anti-CD4 (BD, clone SK3, 1:50), BUV737 anti-CD8 (BD, clone SK1, 1:500), BV711 anti-CD19 (BD, clone SJ25C1,1:25), BV421 anti-CD20 (BD, clone 2H7, 136 1:25), BV786 anti-CD27 (BD, clone L128, 1:50), PE-CF594 anti-IgD (Biolegend, San Diego, 137 CA, USA, clone IA6-2, 1:500) for basic immunophenotyping of cell populations of interest. 138 Quantitative analysis was done using the following intracellular fluorochrome-labeled 139 antibodies: PE anti-STAT1 (BD, clone 1/Stat1, 1:10), FITC anti-pSTAT1 (BD, clone 4a, 3:20), 140 AF647 anti-pSTAT2 (R&D Systems, clone 1021D, 1:5), PE anti-IRF1 (BD, clone 20/IRF-1, 141 142 1:20), AF647 anti-IRF7 (BD, clone K47-671, 1:10). For IRF9 analysis an unconjugated IRF9 143 antibody (Thermo Fisher, isotype rabbit IgG, clone 14H9L22, 1:100) was applied. After staining

perpetuity. All rights reserved. No reuse allowed without permission.

and washing cells, a secondary antibody was used for specific binding of IRF9 (Jackson 144 145 Immuno Research, isotype donkey anti rabbit IgG, polyclonal, 1:100). Number of absolute B cells was measured with Trucount (BD) and samples were processed according to the 146 manufacturer's instruction. As a control, at least one healthy control sample was processed 147 148 simultaneously with patients' samples. Siglec-1 (CD169) expression analysis on CD14+ 149 monocytes was performed at baseline as previously described [19].

150 2.3. Isolation of peripheral blood mononuclear cells (PBMCs)

151

154

Peripheral blood mononuclear cells (PBMCs) were obtained by density gradient centrifugation 152 using Ficoll-Paque PLUS (GE Healthcare Bio-Sciences, Chicago, IL, USA). 153

Functional analysis of IFNα and IFNγ signaling pathways 155 2.4.

156 In order to evaluate the functional cellular responsiveness upon IFN stimuli, stimulation 157 158 experiments were carried out as previously described [18]. In brief, we suspended isolated 159 PBMCs in RPMI medium (GlutaMAX, Life Technologies, Paisley, UK) and stimulated with IFNα2a (100 ng/ml for 5 min and 5 ng/ml 48h) (Recombinant Human, Milteny, Germany) or 160 IFNy1b (100 ng/ml for 5 min and 5 ng/ml 48h) (Recombinant Human, Milteny, Germany). Cells 161 162 were then harvested, washed, lysed, permeabilized and stained using the same staining as 163 mentioned above followed by flow cytometry.

164

2.5. **Statistical analysis** 165

166 Flow cytometry data were analysed using FACSDiva software (Becton Dickinson, Franklin 167 Lakes, NJ, USA) and FlowJo (version 10, TreeStar, Ashland, OR, USA). For graphical and 168 statistical analysis, GraphPad Prism (version 7.00, GraphPad Software, La Jolla, CA, USA) 169 170 was used. Mann–Whitney tests were used for the comparison of two groups. For multiple group 171 comparison, two-way ANOVA with Sidák's post-test for multiple comparison. Spearman 172 correlation coefficient was calculated to detect possible associations between parameters or 173 disease activity, respectively. P-values < 0.05 were considered significant. Correlation matrix 174 was calculated using base R and corrplot package (R Foundation for Statistical Computing) 175 using Spearman method.

177 3. Results

179 3.1. **Cohort characteristics**

180 In the current cohort, we included 17 out-patients with mild COVID-19 during their guarantine 181 (WHO 8-point ordinal scale 1 and 2) and 13 hospitalized patients treated for severe COVID-182 19 pneumonia on an Intensive Care Unit (ICU) (WHO 8-point ordinal scale \geq 4) (Table 1) [15]. 183 Age and days post symptom onset were not significantly different between both groups, while 184 more patients with mild COVID-19 were female. Among patients with severe disease 185 manifestation, 6 patients subsequently died because of COVID-19. 186

187

176

178

188 3.2. **Reduced STAT1 expression in patients with severe COVID-19**

189 Since severe COVID-19 has a highly impaired IFN type I signature, with especially reduced IFN-α production and activity [20], we initially asked how the major effector downstream targets 190 of type I IFN are affected among patients with COVID-19. We found a significantly increased 191 192 STAT1 protein expression in all analyzed cell subsets from whole blood analysis, including T 193 cells (CD4⁺ and CD8⁺), B cells (IgD⁺CD27⁻ (Naïve), IgD⁺CD27⁺ (PreSwitch), IgD⁻CD27⁺ (PostSwitched) and IgD⁻CD27⁻ (Double Negative, DN)), plasmablasts (CD20^{low}CD27^{high)} and 194 195 monocytes (CD14⁺) from all patients with COVID-19 compared to healthy controls (Figure 1 196 C-E). Most notably, reduced STAT1 was observed in severe COVID-19 cases compared to perpetuity. All rights reserved. No reuse allowed without permission.

197 mild COVID-19 cases in particular in CD14+ monocytes and plasmablasts, respectively (Fig 198 1D and Fig 1E).

Since STAT1 signaling is mainly regulated through phosphorylation, we were interested in the 199 phosphorylated form of STAT1. Baseline pSTAT1 was significantly increased in monocytes, 200 CD4+ and CD8+ T cells, pre-switched B cells (IgD+CD27+) and plasmablasts from severe 201 202 COVID-19 patients compared to healthy controls (Figure 1F-H).

203 To better understand the relation between the expression of full protein STAT1 and phosphorylated protein (pSTAT1), the ratio of pSTAT1/STAT1 was obtained. A reduced ratio 204 205 of pSTAT1/STAT1 was observed in plasmablasts and CD14⁺ cells from COVID-19 patients with mild disease compared to those with severe disease (Figure S1A). No differences in 206 pSTAT2 levels were observed among study groups (Figure S1B). These results suggest that 207 mildly affected COVID-19 patients increased their STAT1 expression, but not their detectable 208 209 levels of phosphorylation, while severely affected COVID-19 patients showed a greater 210 increase of phosphorylation in relation to the increase of total STAT1 expression. Thus, there is a substantial impairment to increase STAT1 transcription in severe COVID-19 that especially 211 212 affects CD14+ monocytes and plasmablasts.

3.3. **Reduced IRF9 expression in patients with severe COVID-19** 213

214

215 STAT1 is part of interferon mediated viral response, representing a key component of 216 complexes like ISGF3 and GAS, responsible for amplified interferon-mediated signals [12]. To better understand the nature of STAT1 alteration in patients with COVID-19, IRF9 217 218 (components of ISGF3 and GAS complexes) was evaluated. An increased IRF9 expression was found in CD8⁺ T cells, IgD⁺CD27⁻, IgD⁺CD27⁺, IgD⁻CD27⁺ and IgD⁻CD27⁻ B cells, PB and 219 220 CD14⁺ cells from patients with mild COVID-19 compared to healthy controls (Fig. 2B, C). Similar to STAT1, severe COVID-19 was characterized by reduced IRF9 expression compared 221 222 to mild COVID-19, in PB and CD14+ cells (Figure 2 A-C). Patients with severe COVID-19 had 223 lower IRF9 expression compared to mild cases, consistent with a reduced STAT1 expression. 224 Regarding the expression of IRF1, a molecule well known to directly bind and impact the ISRE [12], we found no difference between healthy controls and patients with COVID-19 irrespective 225 226 of severity in T cells, and IgD⁺CD27⁺, IgD⁺CD27⁺, IgD⁻CD27⁺ and IgD⁻CD27⁻ B cells while in CD14+ monocytes and plasmablasts, IRF1 was significantly increased among patients with 227 228 mild or severe COVID-19 compared to healthy controls (Fig. 2 D-F).

Expression of intracellular phosphorylated (pS477/pS479) IRF7 did not significantly differ 229 230 between all groups studied and between the different T and B cell populations (Fig. 2 G-I). 231 Only in monocytes, IRF7 was reduced in severely affected COVID-19 patients compared to mild cases and healthy controls. 232

233

234 3.4. **Correlation of STAT1 with IFN signature**

235 We wondered how these findings interrelate especially with regard to the IFN- signature, which 236 was assessed by the expression of the surrogate marker Siglec-1 (CD169) on monocytes [20]. 237 In our cohort we observed a significant reduction of Siglec-1 expression in severely affected COVID-19 patients (Figure 3A). Siglec-1 and STAT1 showed a significant correlation with in 238 CD3+ T cells, CD19+ B cells and monocytes (Figure 3B), while pSTAT1 did not significantly 239 correlate with Siglec-1 as a surrogate for IFN signature or e.g. age (Figure 3C). Also STAT1 240 241 and IRF9 both components of the ISGFR3 did not correlate (Figure 3C).

242 3.5. Reduced STAT1 response upon IFN stimulation in severe COVID-19

To further evaluate the functionality of type I and II IFN signaling in the context of our finding 243 of reduced baseline whole protein expression of STAT1, we stimulated PBMCs of healthy 244 controls, mildly and severely affected COVID-19 patients with low doses of either IFN-a or IFN-245 246 y for 48h. As a control unstimulated cells (RPMI) of each group were used. Stimulation with

perpetuity. All rights reserved. No reuse allowed without permission.

IFN-α led to a transcriptional upregulation of STAT1 in CD3+ T cells and CD19+ B cells in 247 248 healthy controls and in mild COVID-19 cases in CD19+ B cells (Fig 4A). In severe COVID-19 cases, a tendency of upregulation of STAT1 was observed (Figure 4A). The phosphorylation 249 of STAT1 after low dose IFN-a or IFN-y stimulation for 48 hours remained unchanged in 250 251 healthy controls and mildly affected COVID-19 patients, while its was enhanced in severely 252 affected COVID-19 patients already in unstimulated cells and without further increase after 48h incubation with IFN-α or IFN-γ (Figure 4B). Short term stimulation with higher doses of IFN-α 253 254 was not able to increase pSTAT1 in severe COVID-19 cases. IFN-y stimulation did not impact STAT1 phosphorylation (Figure 4C). 255

256

257 4. Discussion

COVID-19 is characterized by excessive production of multiple pro-inflammatory cytokines [21. 258 22] and patients with severe COVID-19 have a highly impaired IFN type I signature, in 259 260 particular reduced IFN-a production and activity [6]. A common signaling route of cytokines, including IFNs is the JAK STAT signaling pathway [23]. JAKs and STATs provide a highly 261 262 complex but orchestrated system of heterogeneous molecules with specific signaling through defined receptor complexes including recruitment of different STATs and resulting in specific 263 264 downstream transcription [7].

In this study we describe an upregulation of STAT1 and IRF9 in mildly and severely affected 265 266 COVID-19 patients, which correlated with the IFN-signature reflected by Siglec-1 surface 267 expression. Both, Siglec-1 and STAT1 were lower among severely affected COVID-19 patients compared to mildly affected COVID-19 patients, especially in plasmablasts and monocytes. 268 This is of particular interest since, these two cell types are considered the main players of 269 pathogenesis in severe COVID-19 [24, 25]. The data suggest that certain viral factors may limit 270 proper STAT1 and IRF9 function in severe COVID-19 patients in these cells and that the 271 inhibition of translocation of STATs is more pronounced than the inhibition of phosphorylation 272 [13, 14]. These results are in accordance with other authors, showing Siglec-1 expression 273 274 correlate with viral load in mild COVID patients, but in severe COVID patients [26].

275 Increased levels of STAT1 in B cells were previously reported in SLE patients which correlate 276 with Siglec-1 expression on CD14+ monocytes [18]. In a similar way, SLE patients have 277 increased levels of the STAT1 protein in CD4+ T cells, alteration associated with perturbed 278 homeostasis of regulatory T cells and disease severity [27]. Discordant to the whole protein 279 levels, the phosphorylation of STAT1 is enhanced in severely affected COVID-19 patients 280 suggesting a dysbalanced JAK STAT signaling that fails to induce transcription of the ISRE. An increased pSTAT1 is also present without stimulation in cultured PBMCS (here CD19+ B 281 282 cells and CD3+ cells) and no further increase by IFN- α or IFN-y stimulation is achieved. 283 Further, this intervention could not demonstrate a transcriptional increase of STAT1 which would indicate reversibility of this condition. 284

285 Interestingly, phosphorylation of STAT1 in response to IFN stimulation can persist for hours, 286 but newly synthesized unphosphorylated STAT1 induced by pSTAT1 can persist for several days [28]. This suggest high levels of unphosphorylated STAT1 in COVID patients were 287 synthetized in response to persistent type I IFN signaling. It is worth to note that cells treated 288 with lentivirus which exhibited increase in STAT1, did not completely phosphorylated in 289 290 response to IFN stimulation [29]. Data shows that the antiviral role of STAT1 is not completely dependent of phosphorylation and suggests a role of alternative unphosphorylated STAT1 291 292 mediated pathways in COVID-19.

The reduced Siglec-1 expression on the surface of CD14+ monocytes of patients suffering 293 294 from severe COVID-19 compared to patients with mild COVID-19 is consistent with published 295 data [30-32]. As a result of this finding and efficient analysis of Siglec-1 (CD169) on CD14+

perpetuity. All rights reserved. No reuse allowed without permission.

cells, we started to routinely measure Siglec-1 in all patients with COVID-19 admitted to ICUs 296 297 to distinguish between patients with high and low interferon signature to test the hypothesis of an association of IFN signature and outcome of the patients. 298

Absence of correlation between STAT1 and pSTAT1 with IRF9, suggest that an alternative 299 300 IRF9 independent signaling [12] could have a role in COVID-19. Previously, it was reported for 301 IRF9 knock-out mice that type I IFN mediates a potent inflammatory response associated with a more severe neurological disease [33]. Varicella zoster virus prevents type I IFN response 302 303 reducing IRF9 and inhibition of STAT2 phosphorylation in infected cells [34]. IRF9 also prevents exhaustion of CD8+ T cells in Lymphocytic choriomeningitis infection [35]. 304 305 Interestingly, SARS-CoV-2 spike transfected cells secrete miR-148a and -590 via exosomes which induce degradation of IRF9 in human microglia [36]. 306

Currently, optimal treatment for patients with COVID-19 is still uncertain and both interventions, 307 blocking of IFN signaling by JAK STAT inhibition [37, 38] or the use of different types of IFN 308 309 as substitutions have been suggested as a treatment for COVID-19 and showed efficacy in small clinical trials [39, 40]. Thus, the key question raises which intervention is appropriate for 310 311 which patient? In patients with high IFN signaling that are likely in an early stage of the disease. 312 inhibition strategies appear to be attractive especially during the phase of cytokine storm. On the other hand, patients with inability to increase antiviral response are likely in severe stage 313 of disease, IFN substitution may hold more promise than further inhibition. 314

315 The current data indicate severe impairment of STAT1 and IRF9 in severely infected COVID-19 patients consistent with inappropriate type IFN upregulation as a potential mechanism for 316 317 enhanced disease severity. It appears of utmost importance to understand the underlying mechanisms in more detail as patients with diminished type IFN response may benefit from 318 319 targeted therapies. In this regard, JAK STAT inhibition may hold promise for patients with higher STAT1 expression (mild cases), while patients with low Siglec-1 and unable inability to 320 increase antiviral response may benefit from IFN substitution. 321

322 5. **Conflict of Interest Statement**

The authors declare that the research was conducted in the absence of any commercial or 323 financial relationships that could be construed as a potential conflict of interest. 324

325

6. **Ethics Statement** 326

This study was carried out in accordance with the recommendations of the ethics' committees 327 328 at the Charité University Hospital Berlin and University of Ulm with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration 329 330 of Helsinki.

331

7. **Author Contributions** 332

333

- 334 ES, AA, JR, DK, DZ and LS enrolled patients and collected samples.
- HR, ES, FSZ, LS and AA analyzed the data. 335
- SK, HS provided patients within the clinical trial. 336
- 337 KUE, TD, AL, ES and HS supervised the work and acquired funding
- 338 All authors developed, read, and approved the current manuscript.
- 8. Funding 339

perpetuity. All rights reserved. No reuse allowed without permission.

ES was funded by the Federal Ministry of Education and Research (BMBF) grant BCOVIT, 340 341 01KI20161. ES received a grant by the Berlin Institute of Health with the Charité Clinician Scientist Program funded by the Charité –Universitätsmedizin Berlin and the Berlin Institute of 342 Health. ALS is funded by a scholarship of the German Society of Rheumatology. TD is 343 grantholder oft the Deutsche Forschungsgemeinschaft grants KO 2270/7 1, KO-2270/4-1 (KK); 344 Do491/7-5, 11-1, Transregio 130 TP24. HRA holds a scholarship of the COLCIENCIAS 345 scholarship No. 727, 2015. The CAPSID trial was funded by the German Federal Ministry of 346 347 Health (Bundesministerium für Gesundheit) to HS and SK.

9. References 348

- Platanias, L. C., Mechanisms of type-I- and type-II-interferon-mediated signalling. 349 1 Nat Rev Immunol 2005. 5: 375-386. 350
- 351 2 Vivier, E., Tomasello, E., Baratin, M., Walzer, T. and Ugolini, S., Functions of natural killer cells. Nat Immunol 2008. 9: 503-510. 352
- 3 Bonjardim, C. A., Interferons (IFNs) are key cytokines in both innate and adaptive 353 354 antiviral immune responses--and viruses counteract IFN action. *Microbes Infect* 2005. 355 **7**: 569-578.
- 356 4 Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H. H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Beziat, V., Manry, J., Shaw, E., 357 Haljasmagi, L., Peterson, P., Lorenzo, L., Bizien, L., Trouillet-Assant, S., Dobbs, 358 K., de Jesus, A. A., Belot, A., Kallaste, A., Catherinot, E., Tandjaoui-Lambiotte, 359 Y., Le Pen, J., Kerner, G., Bigio, B., Seeleuthner, Y., Yang, R., Bolze, A., Spaan, 360 A. N., Delmonte, O. M., Abers, M. S., Aiuti, A., Casari, G., Lampasona, V., 361 Piemonti, L., Ciceri, F., Bilguvar, K., Lifton, R. P., Vasse, M., Smadja, D. M., 362 Migaud, M., Hadjadj, J., Terrier, B., Duffy, D., Quintana-Murci, L., van de Beek, 363 D., Roussel, L., Vinh, D. C., Tangye, S. G., Haerynck, F., Dalmau, D., Martinez-364 Picado, J., Brodin, P., Nussenzweig, M. C., Boisson-Dupuis, S., Rodriguez-365 Gallego, C., Vogt, G., Mogensen, T. H., Oler, A. J., Gu, J., Burbelo, P. D., Cohen, 366 J. I., Biondi, A., Bettini, L. R., D'Angio, M., Bonfanti, P., Rossignol, P., Mayaux, 367 J., Rieux-Laucat, F., Husebye, E. S., Fusco, F., Ursini, M. V., Imberti, L., Sottini, 368 A., Paghera, S., Quiros-Roldan, E., Rossi, C., Castagnoli, R., Montagna, D., 369 Licari, A., Marseglia, G. L., Duval, X., Ghosn, J., Lab, H., Group, N.-U. I. R. t. C., 370 Clinicians, C., Clinicians, C.-S., Imagine, C. G., French, C. C. S. G., Milieu 371
- 372 Interieur, C., Co, V. C. C., Amsterdam, U. M. C. C.-B., Effort, C. H. G., Tsang, J. S., Goldbach-Mansky, R., Kisand, K., Lionakis, M. S., Puel, A., Zhang, S. Y., 373 Autoantibodies against type I IFNs in patients with life-threatening COVID-19. 374 375 Science 2020. **370**.
- Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, 376 5 M., Sabli, I. K. D., Hodeib, S., Korol, C., Rosain, J., Bilguvar, K., Ye, J., Bolze, A., 377 Bigio, B., Yang, R., Arias, A. A., Zhou, Q., Zhang, Y., Onodi, F., Korniotis, S., 378 Karpf, L., Philippot, Q., Chbihi, M., Bonnet-Madin, L., Dorgham, K., Smith, N., 379 380 Schneider, W. M., Razooky, B. S., Hoffmann, H. H., Michailidis, E., Moens, L., Han, J. E., Lorenzo, L., Bizien, L., Meade, P., Neehus, A. L., Ugurbil, A. C., 381 Corneau, A., Kerner, G., Zhang, P., Rapaport, F., Seeleuthner, Y., Manry, J., 382 Masson, C., Schmitt, Y., Schluter, A., Le Voyer, T., Khan, T., Li, J., Fellay, J., 383 Roussel, L., Shahrooei, M., Alosaimi, M. F., Mansouri, D., Al-Saud, H., Al-Mulla, 384 F., Almourfi, F., Al-Muhsen, S. Z., Alsohime, F., Al Turki, S., Hasanato, R., van de 385 Beek, D., Biondi, A., Bettini, L. R., D'Angio, M., Bonfanti, P., Imberti, L., Sottini, 386 A., Paghera, S., Quiros-Roldan, E., Rossi, C., Oler, A. J., Tompkins, M. F., Alba, 387 388 C., Vandernoot, I., Goffard, J. C., Smits, G., Migeotte, I., Haerynck, F., Soler-Palacin, P., Martin-Nalda, A., Colobran, R., Morange, P. E., Keles, S., Colkesen, 389 F., Ozcelik, T., Yasar, K. K., Senoglu, S., Karabela, S. N., Rodriguez-Gallego, C., 390 Novelli, G., Hraiech, S., Tandjaoui-Lambiotte, Y., Duval, X., Laouenan, C., 391 Clinicians, C.-S., Clinicians, C., Imagine, C. G., French, C. C. S. G., Inborn errors 392 393 of type I IFN immunity in patients with life-threatening COVID-19. Science 2020. 370.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.13.21262006; this version posted August 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

394	6	Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Pere, H.,						
395		Charbit, B., Bondet, V., Chenevier-Gobeaux, C., Breiliat, P., Carlier, N., Gauzit,						
396		R., Morbieu, C., Pene, F., Marin, N., Roche, N., Szwebel, T. A., Merkling, S. H.,						
397		Treluyer, J. M., Veyer, D., Mouthon, L., Blanc, C., Tharaux, P. L., Rozenberg, F.,						
398		Fischer, A., Duffy, D., Rieux-Laucat, F., Kerneis, S. and Terrier, B., Impaired type						
399		I interferon activity and inflammatory responses in severe COVID-19 patients.						
400		Science 2020. 369 : 718-724.						
401	7	Shuai, K., Ziemiecki, A., Wilks, A. F., Harpur, A. G., Sadowski, H. B., Gilman, M.						
402		Z. and Darnell, J. E., Polypeptide signalling to the nucleus through tyrosine						
403		phosphorylation of Jak and Stat proteins. Nature 1993. 366: 580-583.						
404	8	Darnell, J. E., Jr., Kerr, I. M. and Stark, G. R., Jak-STAT pathways and						
405		transcriptional activation in response to IFNs and other extracellular signaling						
406		proteins. Science 1994. 264: 1415-1421.						
407	9	Banninger, G. and Reich, N. C., STAT2 nuclear trafficking, J Biol Chem 2004, 279:						
408	•	39199-39206						
409	10	Paul, A., Tang, T. H. and Ng, S. K., Interferon Regulatory Factor 9 Structure and						
410	10	Regulation Front Immunol 2018 9: 1831						
410 A11	11	Platanitis F Demiroz D Schneller A Fischer K Canelle C Hartl M						
412 412		Gossenreiter T Muller M Novatchkova M and Decker T A molecular switch						
412 /12		from STAT2-IRF0 to ISGE3 underlies interferon-induced gene transcription. Nat						
413		Commun 2010. 10: 2021						
414 415	10	Michalcka A Plactoryk K Wasaly L and Pluyeson H A P A Desitive						
415	12	Faceback Amplifier Circuit That Degulates Interferen (IEN) Stimulated Cone						
410		Every provide and Controls Type L and Type II IEN Despension of Controls 2019 0						
417		Expression and Controls Type I and Type II IFN Responses. From Immunoi 2016. 9.						
418	10	1100. Ww. V. Mall. Zhwang, Z. Cai, C. Zhao, Z. Zhaw, L. Zhang, L. Wang, D. L.						
419	13	Wu, Y., Ma, L., Zhuang, Z., Cal, S., Zhao, Z., Zhou, L., Zhang, J., Wang, P. H.,						
420		Zhao, J. and Cui, J. , Main protease of SARS-Cov-2 serves as a birunctional						
421		The second secon						
422		Ther 2020. 5: 221.						
423	14	Lei, X., Dong, X., Ma, R., Wang, W., Xiao, X., Tian, Z., Wang, C., Wang, Y., Li, L.,						
424		Ren, L., Guo, F., Zhao, Z., Zhou, Z., Xiang, Z. and Wang, J., Activation and evasion						
425	4 5	of type I Interferon responses by SARS-Cov-2. Nat Commun 2020. 11: 3810.						
426	15	Dodd, L. E., Follmann, D., Wang, J., Koenig, F., Korn, L. L., Schoergenhoter, C.,						
427		Proschan, M., Hunsberger, S., Bonnett, T., Makowski, M., Belhadi, D., Wang, Y.,						
428		Cao, B., Mentre, F. and Jaki, T., Endpoints for randomized controlled clinical trials						
429		for COVID-19 treatments. <i>Clin Trials</i> 2020. 17 : 472-482.						
430	16	Kurth, F., Roennefarth, M., Thibeault, C., Corman, V. M., Muller-Redetzky, H.,						
431		Mittermaier, M., Ruwwe-Glosenkamp, C., Heim, K. M., Krannich, A., Zvorc, S.,						
432		Schmidt, S., Kretzler, L., Dang-Heine, C., Rose, M., Hummel, M., Hocke, A.,						
433		Hubner, R. H., Opitz, B., Mall, M. A., Rohmel, J., Landmesser, U., Pieske, B.,						
434		Knauss, S., Endres, M., Spranger, J., Mockenhaupt, F. P., Tacke, F., Treskatsch,						
435		S., Angermair, S., Siegmund, B., Spies, C., Weber-Carstens, S., Eckardt, K. U.,						
436		Schurmann, D., Uhrig, A., Stegemann, M. S., Zoller, T., Drosten, C., Suttorp, N.,						
437		Witzenrath, M., Hippenstiel, S., von Kalle, C. and Sander, L. E., Studying the						
438		pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective						
439		COVID-19 patient cohort (Pa-COVID-19). Infection 2020. 48: 619-626.						
440	17	Körper, S., Weiss, M., Zickler, D., Wiesmann, T., Zacharowski, K., M.Corman, V.,						
441		Grüner, B., Ernst, L., Spieth, P., Lepper, P. M., Bentz, M., Zinn, S., Paul, G.,						
442		Kalbhenn, J., Dollinger, M., Rosenberger, P., Kirschning, T., Thiele, T., Appl, T.,						
443		Mayer, B., Schmidt, M., Drosten, C., Wulf, H., Kruse, J. M., Jungwirth, B.,						
444		Seifried, E. and Schrezenmeier, H., High Dose Convalescent Plasma in COVID-19:						
445		Results from the Randomized Trial CAPSID. medRxiv 2021:						
446		2021.2005.2010.21256192.						
447	18	Aue, A., Szelinski, F., Weissenberg, S. Y., Wiedemann, A., Rose, T., Lino. A. C.						
448		and Dorner, T., Elevated STAT1 expression but not phosphorylation in lupus B cells						

correlates with disease activity and increased plasmablast susceptibility. 449 450 Rheumatology (Oxford) 2020. 59: 3435-3442. 19 Rose, T., Szelinski, F., Lisney, A., Reiter, K., Fleischer, S. J., Burmester, G. R., 451 452 Radbruch, A., Hiepe, F., Grutzkau, A., Biesen, R. and Dorner, T., SIGLEC1 is a 453 biomarker of disease activity and indicates extraglandular manifestation in primary 454 Sjogren's syndrome. RMD Open 2016. 2: e000292. 20 Biesen, R., Demir, C., Barkhudarova, F., Grun, J. R., Steinbrich-Zollner, M., 455 456 Backhaus, M., Haupl, T., Rudwaleit, M., Riemekasten, G., Radbruch, A., Hiepe, F., Burmester, G. R. and Grutzkau, A., Sialic acid-binding Ig-like lectin 1 expression 457 458 in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis 459 Rheum 2008. 58: 1136-1145. 460 21 Lucas, C., Wong, P., Klein, J., Castro, T. B. R., Silva, J., Sundaram, M., 461 Ellingson, M. K., Mao, T., Oh, J. E., Israelow, B., Takahashi, T., Tokuyama, M., 462 Lu, P., Venkataraman, A., Park, A., Mohanty, S., Wang, H., Wyllie, A. L., Vogels, 463 464 C. B. F., Earnest, R., Lapidus, S., Ott, I. M., Moore, A. J., Muenker, M. C., Fournier, J. B., Campbell, M., Odio, C. D., Casanovas-Massana, A., Yale, I. T., 465 466 Herbst, R., Shaw, A. C., Medzhitov, R., Schulz, W. L., Grubaugh, N. D., Dela Cruz, C., Farhadian, S., Ko, A. I., Omer, S. B. and Iwasaki, A., Longitudinal 467 analyses reveal immunological misfiring in severe COVID-19. Nature 2020. 584: 463-468 469 469. Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., Manson, J. J. 22 470 and HIh Across Speciality Collaboration, U. K., COVID-19: consider cytokine 471 storm syndromes and immunosuppression. Lancet 2020. 395: 1033-1034. 472 473 23 Salas, A., Hernandez-Rocha, C., Duijvestein, M., Faubion, W., McGovern, D., 474 Vermeire, S., Vetrano, S. and Vande Casteele, N., JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020. 475 476 **17**: 323-337. 477 24 Ferreira-Gomes, M., Kruglov, A., Durek, P., Heinrich, F., Tizian, C., Heinz, G. A., Pascual-Reguant, A., Du, W., Mothes, R., Fan, C., Frischbutter, S., Habenicht, K., 478 479 Budzinski, L., Ninnemann, J., Jani, P. K., Guerra, G. M., Lehmann, K., Matz, M., Ostendorf, L., Heiberger, L., Chang, H. D., Bauherr, S., Maurer, M., Schonrich, 480 G., Raftery, M., Kallinich, T., Mall, M. A., Angermair, S., Treskatsch, S., Dorner, 481 482 T., Corman, V. M., Diefenbach, A., Volk, H. D., Elezkurtaj, S., Winkler, T. H., Dong, J., Hauser, A. E., Radbruch, H., Witkowski, M., Melchers, F., Radbruch, A. 483 and Mashreghi, M. F., SARS-CoV-2 in severe COVID-19 induces a TGF-beta-484 dominated chronic immune response that does not target itself. Nat Commun 2021. 485 486 **12**: 1961. 25 Kosyreva, A., Dzhalilova, D., Lokhonina, A., Vishnyakova, P. and Fatkhudinov, 487 T., The Role of Macrophages in the Pathogenesis of SARS-CoV-2-Associated Acute 488 489 Respiratory Distress Syndrome. Front Immunol 2021. 12: 682871. 490 26 Doehn, J. M., Tabeling, C., Biesen, R., Saccomanno, J., Madlung, E., Pappe, E., Gabriel, F., Kurth, F., Meisel, C., Corman, V. M., Hanitsch, L. G., Treskatsch, S., 491 492 Heim, K., Stegemann, M. S., Ruwwe-Glosenkamp, C., Muller-Redetzky, H. C., Uhrig, A., Somasundaram, R., Spies, C., von Bernuth, H., Hofmann, J., Drosten, 493 C., Suttorp, N., Witzenrath, M., Sander, L. E. and Hubner, R. H., CD169/SIGLEC1 494 495 is expressed on circulating monocytes in COVID-19 and expression levels are 496 associated with disease severity. Infection 2021. 49: 757-762. Goropevsek, A., Gorenjak, M., Gradisnik, S., Dai, K., Holc, I., Hojs, R., Krajnc, I., 497 27 498 Pahor, A. and Avcin, T., Increased Levels of STAT1 Protein in Blood CD4 T Cells 499 from Systemic Lupus Erythematosus Patients Are Associated with Perturbed Homeostasis of Activated CD45RA(-)FOXP3(hi) Regulatory Subset and Follow-Up 500 Disease Severity. J Interferon Cytokine Res 2017. 37: 254-268. 501 502 28 Lehtonen, A., Matikainen, S. and Julkunen, I., Interferons up-regulate STAT1, 503 STAT2, and IRF family transcription factor gene expression in human peripheral

504		blood mononuclear cells and macrophages. The Journal of Immunology 1997. 159:
505	00	794-803.
506	29	Cheon, H. and Stark, G. R., Unphosphorylated STAT1 prolongs the expression of
507		interferon-induced immune regulatory genes. Proc Natl Acad Sci U S A 2009. 106:
508		9373-9378.
509	30	Ortillon, M., Coudereau, R., Cour, M., Rimmele, T., Godignon, M., Gossez, M.,
510		Yonis, H., Argaud, L., Lukaszewicz, A. C., Venet, F. and Monneret, G., Monocyte
511		CD169 expression in COVID-19 patients upon intensive care unit admission.
512		<i>Cytometry A</i> 2021. 99 : 466-471.
513	31	Bourgoin, P., Soliveres, T., Barbaresi, A., Loundou, A., Belkacem, I. A., Arnoux,
514		I., Bernot, D., Loosveld, M., Morange, P. E., Michelet, P., Malergue, F. and
515		Markarian, T., CD169 and CD64 could help differentiate bacterial from CoVID-19 or
516		other viral infections in the Emergency Department. Cytometry A 2021. 99: 435-445.
517	32	Bedin, A. S., Makinson, A., Picot, M. C., Mennechet, F., Malergue, F., Pisoni, A.,
518		Nyiramigisha, E., Montagnier, L., Bollore, K., Debiesse, S., Morquin, D.,
519		Veyrenche, N., Renault, C., Foulongne, V., Bret, C., Bourdin, A., Le Moing, V.,
520		Van de Perre, P. and Tuaillon, E., Monocyte CD169 Expression as a Biomarker in
521		the Early Diagnosis of Coronavirus Disease 2019. J Infect Dis 2021. 223: 562-567.
522	33	Hofer, M. J., Li, W., Lim, S. L. and Campbell, I. L., The type I interferon-alpha
523		mediates a more severe neurological disease in the absence of the canonical
524		signaling molecule interferon regulatory factor 9. The Journal of neuroscience : the
525		official journal of the Society for Neuroscience 2010. 30: 1149-1157.
526	34	Verweij, M. C., Wellish, M., Whitmer, T., Malouli, D., Lapel, M., Joniic, S., Haas, J.
527		G., DeFilippis, V. R., Mahalingam, R. and Fruh, K., Varicella Viruses Inhibit
528		Interferon-Stimulated JAK-STAT Signaling through Multiple Mechanisms. PLoS
529		Pathog 2015, 11 : e1004901
530	35	Huber, M., Suprunenko, T., Ashhurst, T., Marbach, F., Raifer, H., Wolff, S.,
531		Strecker, T., Viengkhou, B., Jung, S. R., Obermann, H. L., Bauer, S., Xu, H. C.,
532		Lang, P. A., Tom, A., Lang, K. S., King, N. J. C., Campbell, I. L. and Hofer, M. J.
533		IRE9 Prevents CD8(+) T Cell Exhaustion in an Extrinsic Manner during Acute
534		Lymphocytic Choriomeningitis Virus Infection J Virol 2017 91
535	36	Mishra R and Baneriea A C SARS-CoV-2 Spike Targets USP33-IRE9 Axis via
536	00	Exosomal miR-148a to Activate Human Microglia Front Immunol 2021 12: 656700
537	37	Havek M F Mansour M Ndetan H Burkes O Corkren R Dulli A Havek
538	07	B Parvez K and Singh S Anti-Inflammatory treatment of COVID-19 pneumonia
520		with tofacitinib alone or in combination with devamethasone is safe and possibly
535		superior to devamethesone as a single agent in a predominantly African American
540		cohort. Mayo Clin Proc Innov Qual Quitcomos 2021
541	38	Wijava I Andhika P Huang I Purwiga A Budiman K V Bashari M H
542	50	Ponjarti I and Poosli P M A. The use of lanus Kinese inhibitors in bespitelized
545		netion to with COVID 10: Systematic review and mate analysis. Clin Enidemial Clab
544		
545	20	Health 2021. 11: 100755.
546	39	Hung, I. F., Lung, K. C., ISO, E. Y., Liu, R., Chung, I. W., Chu, M. Y., Ng, Y. Y.,
547		LO, J., Chan, J., Tam, A. R., Shum, H. P., Chan, V., Wu, A. K., Sin, K. M., Leung,
548		W. S., Law, W. L., Lung, D. C., Sin, S., Yeung, P., Yip, C. C., Zhang, R. R., Fung,
549		A. Y., Yan, E. Y., Leung, K. H., IP, J. D., Chu, A. W., Chan, W. M., Ng, A. C., Lee,
550		R., Fung, K., Yeung, A., Wu, I. C., Chan, J. W., Yan, W. W., Chan, W. M., Chan, J.
551		F., LIE, A. K., ISang, U. I., Uneng, V. U., QUE, I. L., LAU, U. S., Unan, K. H., IO, K.
552		K. and Yuen, K. Y., I riple combination of interferon beta-1b, lopinavir-ritonavir, and
553		ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-
554	40	label, randomised, phase 2 trial. Lancet 2020. 395 : 1695-1704.
555	40	Andreakos, E. and Islodras, S., COVID-19: lambda interferon against viral load and
556		nyperintiammation. <i>EMBO Mol Med</i> 2020. 12 : e12465.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.13.21262006; this version posted August 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure Legends 558

Figure 1 Reduced STAT1 expression in severe COVID-19 patients 559

(A) Schematic depiction of JAK STAT signaling. (B) Gating strategy on whole blood flow 560 cytometry for IgD+CD27- (Naïve), IgD+CD27+ (PreSwitch), IgD-CD27+ (PostSwitched) and 561 562 IgD-CD27- (Double Negative, DN) as well as CD4+ and CD8+ T cells, (C) Representative histograms of baseline expression of STAT1 on B cells from healthy controls (grey), mild 563 (blue) and severe (red) COVID-19 patients. (D) Median fluorescence intensity (MFI) of 564 STAT1 in CD3+, CD19+ and CD14+ cells. (E) MFI of STAT1 in T and B cell subsets (as 565 566 described in B). (F) Representative histograms of baseline expression of pSTAT1 on B cells from healthy controls (grey), mild (blue) and severe (red) COVID-19 patients. (G) 567 MFI of STAT1 in CD3+, CD19+ and CD14+ cells. (H) MFI of pSTAT1 in T and 568 B cell subsets (as described in B). Median and data from healthy controls (n=20), mild COVID-569 570 19 (n=17) and severe COVID-19 (n=13) patients. Two way ANOVA with Sidack post-test. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 571

572 Figure 2 Enhanced intracellular IRF9 expression in severe COVID-19

573 (A) Representative histograms of baseline expression of IRF9 on B cells from healthy controls mild (blue) and severe (red) COVID-574 (grey), IRF9 in 575 19 patients. (B) Median fluorescence intensity (MFI) of CD3+, CD19+ and CD14+ cells. 576 (C) MFI of IRF9 B cell subsets (as described in in Т and 577 Fig1B). (D) Representative histograms of baseline expression of IRF1 on B cells healthy controls (grey), mild (blue) and severe (red) COVID-19 patients. (E) MFI of IRF1 in CD3+, 578 CD19+ and CD14+ cells. (F) MFI of IRF1 in T and B cell subsets (as described in Figure 579 580 1B). (G) Representative histograms of baseline expression of IRF7 on B cells from healthy controls (grey), mild (blue) and severe (red) COVID-19 patients. (H) MFI of IRF7 in CD3+, 581 CD19+ and CD14+ cells. (I) MFI of IRF7 in T and B cell subsets (as described in Figure 582 583 1B). Median and data from healthy controls (n=20), mild COVID-19 (n=17) and severe COVID-19 (n=13) patients. Two way ANOVA with Sidack post-test. 584 *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 585

586 Figure 3 Significant correlation of STAT1 and Siglec-1 (CD169)

587 (A) Siglec-1 (CD169) expression on CD14+ monocytes in mild and severe COVID-19 patients. (B) Correlation of Siglec-1 expression on the surface of CD14+ monocytes with 588 589 intracellular STAT1 expression in CD3+ T cells, CD19+ B cells or CD14 + monocytes. Each point represents a donor. Mann-Whitney U test. *p<0.05, **p<0.01. (C) Spearman's correlation 590 matrix showing the correlation of all investigated parameters (STAT1, pSTAT1, pSTAT2, IRF1, 591 IRF7 and IRF9) in relation to the analyzed cell populations (B cells, T cells and monocytes). 592 593 Corresponding correlations are represented by red (negative) or blue (positive) circles. Size 594 and intensity of color refer to the strength of correlation. Data from healthy controls (n=20), 595 mild COVID-19 (n=17) and severe COVID-19 (n=13) patients. Only correlations with $p \le 0.05$ 596 are indicated.

Figure 4 Attenuated pSTAT1 response upon IFN type I and II stimulation in severe 597 598 COVID-19

(A) STAT1 and (B) pSTAT1 expression in CD3+ T cells and CD19+ B cells in culture of PBMCs 599 600 from healthy controls (grey, n=8), mild (blue, n=9) or severe (red, n=7) COVID-19 patients. Cells were stimulated for 48 hours with either IFNa (5ng/ml) or IFNy (5ng/ml) or only RPMI as 601 602 a control. (C) PBMCs of the same donors as in (A) were stimulated with IFNa (100ng/ml) or IFNy (100ng/ml) for 5 minutes. Untreated control values of pSTAT1 were 603 604 subtracted to show the individual increase of STAT1 phosphorylation. Data is presented as

medRxiv preprint doi: https://doi.org/10.1101/2021.08.13.21262006; this version posted August 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

radar diagrams. Two way ANOVA with Sidack post-test. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.

Table 1: Patient characteristics

	Mild COVID (n=17)	Severe COVID (n=13)	Healthy controls (n=20)
Age (median, IQR)	47.4 (34.0; 57.0)	61 (53.5; 69.5)	35 (29.0;47.0)
Female	7	1	14
Days post symptom onset	7 (10; 5.5)	10 (8.5; 15)	
Concomitant antibiotic treatment	0	6	
Immunosuppressive treatment before COVID	4	1	
Dexamethasone	0	12	
Tocilizumab	0	1	
Remdesivir	0	1	
CRP mg/dl	n.a.	116 (85.75; 188)	
WHO Ordinal scale 1	2		
WHO Ordinal scale 2	15		
WHO Ordinal scale 5		6	
WHO Ordinal scale 6		1	
WHO Ordinal scale 8		6	



Fig 2





Fig 3



Delta = MFI_{IFNstimulated} - MFI_{unstimulated}

DN

CD14

 $Delta = MFI_{IFNstimulated} - MFI_{unstimulated}$

DN

CD1/

CD14

Healthy controls
Mild COVID-19
Severe COVID-19

medRxiv preprint doi: https://doi.org/10.1101/2021.08.13.21262006; this version posted August 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Fig. S1 Intracellular pSTAT2 levels and pSTAT1/STAT1 ratio of HD and COVID-19 patients

(A) Ratio of pSTAT1/STAT1 in CD3+, CD19+ and

CD14+ cells. Ratio of pSTAT1/STAT1 in T and B cell subsets (as described in Fig1B). **(B)** Median fluorescence intensity (MFI) of pSTAT2 in CD3+, CD19+ and CD14+ cells. MFI of pSTAT2 in T and B cell subsets (as described in Figure 1B). Median and data from HD (n=21), mild COVID-19 (n=17) and severe COVID-19 (n=13) patients. Two way ANOVA with Sidack post-test. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.